Technology Listings


ARCaPE Cell Lines Expressing shRNAs of Human EPLIN

Application

Highly malignant and metastatic prostate cancer cell line.

Key Benefits
  • Prostate cancer cell line with reduced Epithelial Protein Lost In Neoplasm (EPLIN) expression.
  • Cell line exhibits morphology characteristics of malignant cell lines and increased chemoresistance, migration, and invasion.
Market Summary

Prostate cancer is the most common cancer affecting males in the United States and is the second leading cause of cancer related deaths of males. In 2009, over 200,000 males were newly diagnosed with prostate cancer and prostate cancer resulted in nearly 30,000 deaths. Although the survival rates for prostate cancer have improved due to improvements in cancer detection and increased awareness, survival rates for metastatic prostate cancer remain quite low. To further improve prostate cancer survival rates, there is a large research focus on the mechanisms and treatment of metastatic prostate cancer.

Technical Summary

Prostate cancer is the second leading cause of cancer-related deaths in males in the United States, and the vast majority of those deaths result from metastatic cancer. Researchers at Emory have developed a cell line that could serve as a cell-based model to better understand the mechanisms underlying metastatic prostate cancer. Drs. Wu and Zhang determined that reduced expression of Epithelial Protein Lost In Neoplasm (EPLIN) causes a well-characterized prostate cancer cell line, ARCaPE, to behave more like a metastatic cancer cell line. Specifically, EPLIN-depleted ARCaPE cells have a fibroblast-like morphology, reduction in cell-cell contacts, increased migration and invasion, and increased chemoresistance. This cell line exhibits many of the properties of a metastatic cancer cell line and will be a useful tool for further studies on metastatic prostate cancer.

Developmental Stage

Cell lines have been generated and characterized.

Patent Information
Tech ID: RT006
Published: 5/28/2013
Category
Research Tools

Contact
Justin Burns
Licensing Associate
Emory University
justin.burns@emory.edu

Inventor(s)
Daqing Wu
Shumin Zhang

Keywords
Cell Line
Oncology